Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 15.49% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 20.67% | ||||
| Operating Income | -20.67% | ||||
| Income Before Tax | -19.69% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -19.69% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -19.69% | ||||
| EBIT | -20.67% | ||||
| EBITDA | -20.73% | ||||
| EPS Basic | -18.18% | ||||
| Normalized Basic EPS | -18.75% | ||||
| EPS Diluted | 9.00% | ||||
| Normalized Diluted EPS | -18.75% | ||||
| Average Basic Shares Outstanding | 0.56% | ||||
| Average Diluted Shares Outstanding | 0.56% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||